Pardanani, A <br/><br/>
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.  [electronic resource] 

 -  Leukemia  Oct 2010 
 - 1713-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2010.163  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adaptor Proteins, Signal Transducing<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Blast Crisis--genetics<br/>Chronic Disease<br/>DNA, Neoplasm--genetics<br/>DNA-Binding Proteins--genetics<br/>Dioxygenases<br/>Female<br/>Humans<br/>Intracellular Signaling Peptides and Proteins<br/>Isocitrate Dehydrogenase--genetics<br/>Janus Kinase 2--genetics<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Myeloproliferative Disorders--genetics<br/>Polymerase Chain Reaction<br/>Prognosis<br/>Proteins--genetics<br/>Proto-Oncogene Proteins--genetics<br/>Receptors, Thrombopoietin--genetics